U.S., Sept. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07800533) titled 'Brivaracetam Bioequivalence Assessment' on Aug. 28.
Brief Summary: This study assess the relative bioavailability performance of a test brivaracetam coated tablets compared with the EMA reference product, Briviact(R) 100 mg, in healthy adult volunteers of both sexes under fasting conditions. The pharmacokinetic profiles will be compared to assess whether the test product demonstrates equivalent rate and extent of absorption to the reference formulation.
Study Start Date: Aug. 09, 2024
Study Type: INTERVENTIONAL
Condition:
Bioequivalence Study in Healthy Subjects
Intervention:
DRUG: Briveka (R) 100 mg
Brivaracetam coated table...